Mount Vernon Associates Inc. MD Has $414,000 Stake in Teva Pharmaceutical Industries Limited (TEVA)

Mount Vernon Associates Inc. MD raised its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 20.8% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 12,460 shares of the company’s stock after buying an additional 2,144 shares during the period. Mount Vernon Associates Inc. MD’s holdings in Teva Pharmaceutical Industries Limited were worth $414,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Cribstone Capital Management LLC boosted its position in shares of Teva Pharmaceutical Industries Limited by 3.3% in the first quarter. Cribstone Capital Management LLC now owns 3,141 shares of the company’s stock worth $101,000 after buying an additional 100 shares during the last quarter. Bronfman E.L. Rothschild L.P. raised its stake in Teva Pharmaceutical Industries Limited by 7.8% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 3,617 shares of the company’s stock worth $116,000 after buying an additional 261 shares during the period. FNY Managed Accounts LLC bought a new stake in Teva Pharmaceutical Industries Limited during the first quarter worth $123,000. Sterling Investment Advisors Ltd. raised its stake in Teva Pharmaceutical Industries Limited by 2.6% in the first quarter. Sterling Investment Advisors Ltd. now owns 3,900 shares of the company’s stock worth $125,000 after buying an additional 100 shares during the period. Finally, Financial Architects Inc raised its stake in Teva Pharmaceutical Industries Limited by 2.3% in the first quarter. Financial Architects Inc now owns 4,443 shares of the company’s stock worth $143,000 after buying an additional 100 shares during the period. Institutional investors and hedge funds own 56.27% of the company’s stock.

Teva Pharmaceutical Industries Limited (NYSE TEVA) opened at 18.29 on Wednesday. The company has a market capitalization of $18.58 billion, a P/E ratio of 234.49 and a beta of 0.46. The stock’s 50 day moving average price is $32.05 and its 200 day moving average price is $32.28. Teva Pharmaceutical Industries Limited has a one year low of $18.21 and a one year high of $55.45.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last issued its quarterly earnings data on Thursday, August 3rd. The company reported $0.99 earnings per share for the quarter, missing analysts’ consensus estimates of $1.06 by $0.07. The company had revenue of $5.69 billion for the quarter, compared to analysts’ expectations of $5.72 billion. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. The company’s revenue for the quarter was up 12.9% compared to the same quarter last year. During the same quarter last year, the company earned $1.25 earnings per share. Equities analysts anticipate that Teva Pharmaceutical Industries Limited will post $4.44 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 14th. Investors of record on Tuesday, August 29th will be paid a dividend of $0.085 per share. This represents a $0.34 dividend on an annualized basis and a dividend yield of 1.86%. The ex-dividend date of this dividend is Friday, August 25th. Teva Pharmaceutical Industries Limited’s dividend payout ratio (DPR) is currently -18.95%.

COPYRIGHT VIOLATION NOTICE: “[[title]]” was first published by [[site]] and is the property of of [[site]]. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be accessed at [[permalink]].

A number of analysts have recently weighed in on TEVA shares. Vetr raised Teva Pharmaceutical Industries Limited from a “buy” rating to a “strong-buy” rating and set a $37.48 price objective for the company in a research note on Tuesday, April 11th. Zacks Investment Research raised Teva Pharmaceutical Industries Limited from a “sell” rating to a “hold” rating in a research note on Monday, April 17th. Citigroup Inc. dropped their price objective on Teva Pharmaceutical Industries Limited from $47.00 to $42.00 and set a “buy” rating for the company in a research note on Tuesday, April 25th. Wells Fargo & Company reissued a “market perform” rating on shares of Teva Pharmaceutical Industries Limited in a research note on Saturday, April 29th. Finally, Maxim Group set a $35.00 price objective on Teva Pharmaceutical Industries Limited and gave the company a “hold” rating in a research note on Thursday, May 11th. Two investment analysts have rated the stock with a sell rating, twenty have issued a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. Teva Pharmaceutical Industries Limited currently has a consensus rating of “Hold” and an average price target of $39.19.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.